MétaCan
Menu
Back to cohort
Record W4244757840 · doi:10.1093/neuonc/noz036.192

MEDU-34. PILOT STUDY OF A SURGERY AND CHEMOTHERAPY-ONLY APPROACH IN THE UPFRONT THERAPY OF CHILDREN WITH WNT-POSITIVE STANDARD RISK MEDULLOBLASTOMA

2019· article· en· W4244757840 on OpenAlexaff
Kenneth J. Cohen, Pratiti Bandopadhayay, Susan Chi, Wendy B. London, Fausto J. Rodríguez, Cynthia Hawkins, Edward Yang, Dolly Aguilera, Robert C. Castellino, Tobey J. MacDonald, Stacie Stapleton, David M. Ashley

Bibliographic record

VenueNeuro-Oncology · 2019
Typearticle
Languageen
FieldMedicine
TopicGlioma Diagnosis and Treatment
Canadian institutionsHospital for Sick Children
Fundersnot available
KeywordsMedicineMedulloblastomaRadiation therapyOncologyVincristineChemotherapyInternal medicineSurgeryAdjuvant therapyCyclophosphamidePathology

Abstract

fetched live from OpenAlex

BACKGROUND: Molecular subclassification of medulloblastoma identifies Wnt-positive medulloblastoma (WPM) as a highly favorable subtype with event-free survival (EFS) exceeding 90% when treating patients following near total or complete resection with standard dose craniospinal irradiation and boost radiation to the posterior fossa (XRT) followed by adjuvant chemotherapy. This pilot study explored the safety of omitting XRT in children with standard-risk WPM. METHODS: Subjects had to meet usual standard-risk criteria (< 1.5 cm2 residual tumor, no metastatic spread, no anaplasia) and have a WPM. Initial criteria for determination of WPM included nuclear beta-catenin immunopositivity, monosomy 6 and absence of myc-amplification by FISH. Following the first two subject enrollments, criteria for WPM was revised to no longer require nuclear beta-catenin immunopositivity, and substituted gene-expression profiling by Nanostring. Upon consent, eligible subjects received adjuvant chemotherapy following the Children’s Oncology Group ACNS0331 AAB-AAB-AAB (A=cisplatin/CCNU/VCR; B=cyclophosphamide/vincristine) backbone and followed for EFS. RESULTS: Fourteen children underwent prescreening of which six children who met molecular criteria for WPM elected to enroll on study treatment. Subject #1 completed planned protocol therapy, requiring a 50% reduction in cisplatin for most of therapy for ototoxicity, but relapsed 3 months following the completion of therapy. Subject #2 completed planned protocol therapy without dose reductions or delays, but relapsed 6 months following the completion of therapy. In both cases, relapse was local and disseminated. Following the second relapse, further accrual was halted. Of the remaining 4 subjects, two have recently completed protocol therapy and remain free of disease. The final two subjects are in the midst of protocol therapy. Additional therapy in the form of XRT and/or chemotherapy dose intensification has been recommended to these remaining 4 subjects. CONCLUSIONS: Chemotherapy following ACNS0331, in the absence of XRT, appears to be insufficient for the treatment of non-metastatic WPM.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.004
Threshold uncertainty score0.008

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0010.001
Scholarly communication0.0000.000
Open science0.0010.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.019
GPT teacher head0.270
Teacher spread0.251 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations12
Published2019
Admission routes1
Has abstractyes

Explore more

Same venueNeuro-OncologySame topicGlioma Diagnosis and TreatmentFrench-language works237,207